ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

eculizumab

Also written as “Eculizumab”, “Eculizumab Injection” and “Soliris (eculizumab)”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Myasthenia Gravis · Neuromyelitis Optica · Guillain-Barre Syndrome, led by 4 companies.

Drug pageEculizumab: every studyAll 81 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 23, 200936 company-led studies, 1 open or runningNext primary completion: Dec 7, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca311 open or runningphase 4since Mar 23, 2009Jul 18, 2005Dec 7, 2026phase 3 · NCT06724809
AO GENERIUMits history only20 open or runningphase 3since Jul 3, 2020Jul 3, 2020none ahead
Samsung Bioepisits history only20 open or runningphase 3since Aug 12, 2019Oct 24, 2018none ahead
Biocadits history only10 open or runningphase 3since May 16, 2025May 16, 2025none ahead

Also a collaborator on its studies: CMIC Co, Ltd. Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Jul 18, 2005.

  1. Aug 3, 2011Phase 3 study in Shiga-like Toxin-producing Escherichia ColiNCT01410916 · 198 enrolled · Germany
  2. Mar 27, 2012Phase 2 study in Stage V Chronic Kidney DiseaseNCT01567085 · 80 enrolled · Australia, France, Italy and more
  3. Dec 4, 2012Phase 2 study in Atypical Hemolytic Uremic SyndromeNCT01757431 · 2 enrolled · Japan
  4. Jun 20, 2013Phase 3 study in Neuromyelitis OpticaNCT01892345 · 143 enrolled · United States, Argentina, Australia and more
  5. Nov 18, 20132 phase 3 studiesNCT02003144, NCT01997229
  6. May 15, 2014Phase 3 study in Delayed Graft FunctionNCT02145182 · 288 enrolled · United States, Australia, Brazil and more
  7. Nov 22, 2014Phase 3 study in Myasthenia GravisNCT02301624 · 117 enrolled · United States, Argentina, Belgium and more
  8. Nov 26, 2018Phase 3 study in Myasthenia GravisNCT03759366 · 12 enrolled · United States, Japan
  9. Nov 5, 2019Phase 3 study in Neuromyelitis OpticaNCT04155424 · 5 enrolled · United States, Canada, Germany and more
  10. Mar 23, 2020Phase 4 study in Hemoglobinuria, ParoxysmalNCT04320602 · 18 enrolled · United Kingdom
  11. Feb 9, 2021Phase 3 study in Guillain-Barre SyndromeNCT04752566 · 57 enrolled · Japan
  12. May 17, 20232 phase 3 studiesNCT05876351, NCT05886244
  13. Nov 19, 2024Phase 3 study in Neuromyelitis OpticaNCT06724809 · 21 enrolled · China
  14. Dec 11, 2024Phase 3 study in Myasthenia GravisNCT06764160 · 15 enrolled · China

Ahead

  1. Dec 7, 2026Primary completion: phase 3 study in Neuromyelitis OpticaNCT06724809

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 31 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06764160Myasthenia Gravis · China3CompletedDec 29, 202515
NCT06724809Neuromyelitis Optica · China3Active, not recruitingDec 7, 202621
NCT05886244Hemoglobinuria, Paroxysmal · China3CompletedApr 14, 202525
NCT05876351Atypical Hemolytic Uremic · China3CompletedMay 7, 202525
NCT04752566Guillain-Barre Syndrome · Japan3CompletedAug 3, 202257
NCT04320602Hemoglobinuria, Paroxysmal · United Kingdom4CompletedDec 20, 202218
NCT04155424Neuromyelitis Optica · United States, Canada, Germany and more3TerminatedJul 31, 20235
NCT03759366Myasthenia Gravis · United States, Japan3CompletedJan 6, 202212
NCT02301624Myasthenia Gravis · United States, Argentina, Belgium and more3CompletedJan 15, 2019117
NCT02145182Delayed Graft Function · United States, Australia, Brazil and more3CompletedNov 22, 2016288
NCT02003144Neuromyelitis Optica · United States, Argentina, Australia and more3CompletedJul 12, 2021119
NCT01997229Myasthenia Gravis · United States, Argentina, Australia and more3CompletedFeb 2016125
NCT01892345Neuromyelitis Optica · United States, Argentina, Australia and more3TerminatedJul 17, 2018143
NCT01757431Atypical Hemolytic Uremic Syndrome · Japan2CompletedSep 24, 20132
NCT01567085Stage V Chronic Kidney Disease · Australia, France, Italy and more2CompletedJun 11, 201580
NCT01410916Shiga-like Toxin-producing Escherichia Coli · Germany3CompletedJan 2012198
NCT01399593Antibody Mediated Rejection · United States, Australia, France and more2TerminatedMay 13, 2014102
NCT01194973Atypical Hemolytic Uremic Syndrome · United States, Belgium, France and more2CompletedOct 201344
NCT01193348Atypical Hemolytic Uremic Syndrome · United States, Australia, Belgium and more2CompletedJan 201422
NCT01194804Hemoglobinuria, Paroxysmal2CompletedSep 201027
NCT01192399Hemoglobinuria, Paroxysmal2CompletedJun 200829
NCT00867932Hemoglobinuria, Paroxysmal · United States4CompletedMay 12, 20117
NCT00844844Atypical Hemolytic Uremic Syndrome · United States, Austria, France and more2CompletedSep 20101
NCT00844545Atypical Hemolytic Uremic Syndrome · United States, Austria, France and more2CompletedSep 201016
NCT00844428Atypical Hemolytic Uremic Syndrome · Canada, France, Germany and more2CompletedOct 20105
NCT00838513Atypical Hemolytic Uremic Syndrome · Canada, France, Germany and more2CompletedOct 201015
NCT00727194Myasthenia Gravis · United States, Canada, United Kingdom2TerminatedMar 201114
NCT00485576Allergic Asthma · Canada2CompletedSep 200821
NCT00122317Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3CompletedSep 2008187
NCT00122304Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3Completed85
NCT00122330Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3Completed75

How it is read

Names in the registry

  • “Eculizumab”, 23 entries
  • “eculizumab”, 10 entries
  • “Eculizumab Injection”, 1 entry
  • “Soliris (eculizumab)”, 1 entry
  • “Elizaria®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.